长期生物/靶向治疗对类风湿关节炎骨密度的影响:倾向性评分匹配分析
本研究纳入388例完成3年随访的类风湿关节炎(RA)患者,按倾向性评分1:2匹配后比较生物/靶向合成改善病情抗风湿药(b/tsDMARD)与传统合成改善病情抗风湿药(csDMARD)对骨密度(BMD)的影响。结果显示b/tsDMARD组股骨颈、全髋和腰椎BMD保持稳定,而csDMARD组显著下降;联合抗骨质疏松治疗者BMD保护效果最佳。
要点
- 长期b/tsDMARD治疗对RA患者骨丢失具有保护作用。
- csDMARD组3年后股骨颈、全髋和腰椎BMD显著下降。
- b/tsDMARD联合抗骨质疏松治疗者BMD保护效果最佳。
核心结论
- 长期b/tsDMARD治疗对RA患者骨丢失具有保护作用。
- 联合抗骨质疏松治疗与b/tsDMARD治疗者BMD保护效果最佳。
研究设计与样本
- 研究纳入2014年9月至2019年3月招募的RA患者,随访3年,最终388例完成随访。
- 参与者按NICE指南治疗,记录基线和3年末BMD及脆性骨折证据。
- 按是否接受b/tsDMARD或csDMARD分组,并进行1:2倾向性评分匹配。
主要发现
- 匹配后b/tsDMARD组92例,csDMARD组184例。
- 3年后b/tsDMARD组股骨颈、全髋和腰椎(L1-4)BMD保持稳定(P=0.09、0.15、0.87)。
- csDMARD组相应部位BMD显著下降(P=0.045、<0.001、0.004)。
- 接受b/tsDMARD联合抗骨质疏松治疗者BMD保护效果大于其他亚组。
临床怎么用
- 对RA患者长期使用b/tsDMARD可能有助于减缓骨密度下降。
- 对存在骨丢失风险的RA患者,可考虑b/tsDMARD联合抗骨质疏松治疗以增强BMD保护。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To investigate changes in BMD in RA patients receiving 3-year biological/targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARD) or conventional synthetic DMARD (csDMARD). METHODS: Patients with RA were recruited from September 2014 until March 2019. Clinical characteristics, BMD and evidence of fragility fractures at enrolment were documented. Participants were treated according to the National Institute for Health and Care Excellence (NICE) guidelines over a 3-year observation period. Repeated BMD was measured at the end of the study period. Participants were grouped into those receiving b/tsDMARD or csDMARD and by propensity score matching (1:2). RESULTS: A total of 388 participants completed the 3-year follow-up. After propensity score matching, 92 and 184 participants were allocated to the b/tsDMARD (Group I) and csDMARD (Group II), respectively. After 3 years, BMD remained stable at the femoral neck (FN), hip (total) (TH) and lumbar vertebra (L1-4) (P =0.09, 0.15, 0.87) in Group I. However, BMD decreased significantly in Group II (P=0.045, <0.001, 0.004) at corresponding sites. Participants receiving combined b/tsDMARD and anti-osteoporosis therapy experienced a greater BMD preserving effect than other subgroups. CONCLUSION: Long-term b/tsDMARDs therapy had protective effects on bone loss for patients with RA. Patients receiving concomitant anti-osteoporosis therapy and b/tsDMARDs therapy experienced the greatest BMD preserving effect.
引用
- Chen JF, Hsu CY, Yu SF, et al. The impact of long-term biologics/target therapy on bone mineral density in rheumatoid arthritis: a propensity score-matched analysis. Rheumatology (Oxford). 2020. PMID: 31984422. doi:10.1093/rheumatology/kez655
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。